Pdt Partners, LLC Vertex Pharmaceuticals Inc Transaction History

Pdt Partners, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $1.71 Million - $1.87 Million	-4,200 Reduced 80.61%	1,010 $422,000
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $690,116 - $826,288	-2,012 Reduced 27.86%	5,210 $2.12 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $1.66 Million - $1.78 Million	4,912 Added 212.64%	7,222 $2.51 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $251,536 - $281,528	-800 Reduced 25.72%	2,310 $812,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $880,845 - $1 Million	3,110 New	3,110 $979,000
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $517,616 - $644,487	2,203 Added 8.88%	27,003 $7.61 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $64,654 - $76,203	292 Added 1.19%	24,800 $6.47 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $370,481 - $467,680	-2,093 Reduced 7.87%	24,508 $5.38 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $687,105 - $768,926	3,788 Added 16.6%	26,601 $4.83 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $4.01 Million - $4.73 Million	21,412 Added 1528.34%	22,813 $4.6 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $4.68 Million - $5.46 Million	-22,625 Reduced 94.17%	1,401 $301,000
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $864,059 - $1.15 Million	-4,174 Reduced 14.8%	24,026 $5.68 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $76,695 - $90,930	-300 Reduced 1.05%	28,200 $7.67 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $6.43 Million - $8.43 Million	28,500 New	28,500 $8.27 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.